Clopidogrel combined with rivaroxaban in peripheral artery disease after revascularization.

ABSTRACT:

Background

To evaluate the efficacy and safety of clopidogrel-rivaroxaban combination compared to aspirin-rivaroxaban combination in patients with symptomatic peripheral artery disease (PAD).

Methods

Consecutive patients with symptomatic PAD patients were analyzed from January, 2018 to June, 2022 at Nanjing Drum Tower Hospital. Patients were divided into two groups based on the antithrombotic therapy. The primary efficacy outcome was a composite of major adverse cardiovascular events (MACE) and major adverse limb events (MALE), and the primary safety outcome was major bleeding. Patients were followed until the first occurrence of any outcomes or the study end date (30 June 2024).

Results

A total of 695 patients were enrolled into this study. The clopidogrel-rivaroxaba

SUBMITTER: Lu M 

PROVIDER: S-EPMC11770050 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature